Status: Recruiting
Phase II Clinical Study of BC006 in Patients With Idiopathic Pulmonary Fibrosis
This is a multicenter, Phase II clinical study to evaluate the efficacy and safety of BC006 over a 24-week treatment period in patients with idiopathic pulmonary fibrosis (IPF). The study consists of two phases: an open-label safety run-in phase and a double-blind, randomized, placebo-controlled phase.
Participants needed: 96
Trial details
Phase: Phase 2Age: 40+Biological sex: AllType: InterventionalSponsor: Dragonboat Biopharmaceutical Company LimitedUpdated: May 13, 2026Locations: 1
Eligibility criteria
Must provide written informed consent form (ICF) indicating understanding of the... [+8]
Interstitial lung disease of known etiology (e.g., domestic and occupational env... [+30]